Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature
|
|
- Shawn Austin
- 5 years ago
- Views:
Transcription
1 The Spine Journal 6 (2006) Review Article Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature Faisal T. Sayer, MD, MSc*, Erik Kronvall, MD, Ola G. Nilsson, MD, PhD Department of Neurosurgery, Lund University Hospital, Lund , Sweden Received 27 May 2005; accepted 12 November 2005 Abstract Keywords: BACKGROUND CONTEXT: Methylprednisolone has evolved during the 1990s, through the results obtained from the National Acute Spinal Cord Injury Studies NASCIS II and III, as a standard treatment in acute spinal injury. PURPOSE: To evaluate the scientific basic for the use of methylprednisolone in acute spinal cord injury. STUDY DESING: Systematic review of the accumulated literature. METHODS: Critical evaluation of the data obtained in the NASCIS II and III studies plus other accumulated literature. RESULTS: Analyses have been made on subgroups of the study populations, and the results were based on statistical artefacts. Furthermore, improved functional recovery shown by these studies was not clinically significant. CONCLUSION: There is insufficient evidence to support the use of methylprednisolone as a standard treatment in acute spinal cord injury. Ó 2006 Elsevier Inc. All rights reserved. Methylprednisolone; Spinal cord injury; Spine trauma; Secondary injury; National Acute Spinal Cord Injury Study; NASCIS Introduction Spinal cord injury (SCI) is a catastrophic event that imposes an enormous medical, psychological, social, and economic impact on individuals, families and society [1]. During the First World War, the immediate mortality of SCI was 50-65% [2]. Today, life expectancy after SCI in the industrialized world is only slightly reduced [3,4]. In one study, the mean life expectancy of spinal cord injured people compared with that of the whole population was estimated to approach 70% for individuals with complete tetraplegia, 84% for complete paraplegia, and 92% for patients with an incomplete lesion (spared motor functional capabilities) [4]. Because there is a lack of effective treatment for restoring neurological function below the level of the injury, positive symptoms (such as spasticity and FDA device/drug status: not applicable. Nothing of value received from a commercial entity related to this manuscript. * Corresponding author. Department of Neurosurgery, Lund University Hospital, Lund, Sweden. Tel.: ; fax: address: Faisal.Sayer@neurokir.lu.se (F.T. Sayer) hyperreflexia) that interfere with the remaining function, and increased long-term survival [5], the majority of SCI victims face many years of lost independence and continued medical expenses. In most cases, traumatic SCI is characterized by severe contusion rather that transection of the spinal cord, even when there are massive bony injuries [6]. However, the primary lesion is gradually enlarged by delayed secondary damaging processes [7 9], leading to necrotic changes and cavity formation of the injured spinal cord tissue [9 11]. The exact pathogenesis of secondary spinal cord damage has not been fully elucidated, but there is considerable evidence that it occurs within minutes and continues for days or weeks, resulting in further neurological deterioration [12]. Furthermore, secondary spinal cord damage has the propensity to worsen during the first few hours after injury, and thus treatment during this window of time has the potential to prevent or reduce the resulting neurological deficit. Unfortunately, there is incomplete knowledge of the exact time course of many secondary mechanisms, and therefore the exact therapeutic window in which to treat many of these processes is unknown [13] /06/$ see front matter Ó 2006 Elsevier Inc. All rights reserved. doi: /j.spinee
2 336 F.T. Sayer et al. / The Spine Journal 6 (2006) Treatment of spinal cord injury Surgical intervention following spinal trauma aims at preventing further mechanical damage to the spinal cord through reestablishing the stability of the vertebral column. However, it has not been shown to prevent the posttraumatic neurological deterioration, which starts immediately after injury and can progress over the following months to years [14]. The results of recent clinical studies of neuroprotective pharmacotherapy have shown only modest improvement in neurological recovery and functional capability, such as motor and sensory function, in patients with SCI [15 17]. For monosialotetrahexosylganglioside (GM-1) gangliosides [18 20], tirilazad mesylate [21,22], naloxone [16], and nimodipine [23], more substantial evidence regarding their clinical efficacy is needed. Other current recovery of function treatments such as walkinginduced learning of the cord and 4-aminopyridine (4-AP) are under evaluation; however, their efficacy remains to be confirmed [24 26]. Methylprednisolone (MP) is currently in widespread use for the treatment of acute SCI and is widely considered the gold standard treatment. Methylprednisolone High-dose MP, as recommended on the basis of the National Acute Spinal Cord Injury Studies (NASCIS-2 and NASCIS-3), is the only effective neuroprotective agent tested in controlled multicenter clinical trials [22,27 29]. The recommendation obtained, based on these two studies, was that MP should be given as a bolus dose of 30 mg/kg over 15 minutes, and followed by a continuous infusion of 5.4 mg/ kg/hour. If treatment is initiated within 3 hours after sustaining SCI, the infusion would be for 23 hours (total treatment time of 24 hours). However, if treatment is initiated within 3 8 hours then the infusion should be continued for 47 hours (total treatment time of 48 hours). No MP should be given if the patient arrives 8 hours or more after SCI. MP was tested as an inhibitor of lipid peroxidation and hypothesized to reduce the posttraumatic degenerative changes in the injured spinal cord. However, conflicting experimental reports [30 33] combined with the relatively small neurological improvements in humans [29,34] have prompted some researchers and physicians to question the efficacy of MP for the treatment of acute traumatic SCI [34,35]. The Section on Disorders of the Spine and Peripheral Nerves of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons published in the spring of 2002 the guidelines for the treatment of SCI, and MP was considered most controversial [36]. In May 1999, a survey of every trauma facility medical director in the state of Colorado showed that 98% of the health-care facilities administer steroids to SCI patients. However, approximately half of the medical directors were either uncertain or did not believe that the data regarding the corticosteroid treatment for SCI supported its use [37]. It is probable that many centers still use MP, despite lack of clear evidence of its efficacy, to avoid legal repercussions [38]. In this article, we will review the literature regarding MP as a treatment for SCI. The National Acute Spinal Cord Injury Studies The NASCIS were conducted under the leadership of Michael Bracken at the department of epidemiology and public health at Yale University. All of the three studies were multicenter, randomized, double-blinded clinical trials. NASCIS I In the first study, NASCIS I (1979), a standard dose of MP (100 mg) was compared with a megadose (1,000 mg) given intravenously once daily for 10 days. A total of 330 patients were included in this study and were evaluated with sensory and motor assessment at 6 weeks, 6 months, and 1 year after spinal cord injury. There was no difference between the two groups with respect to either modality at all time points [40]. NASCIS II Later animal experiments have suggested that only much higher doses of MP (compared with NASCIS I) have a neuroprotective effect after SCI. When NASCIS II was conducted in 1985, the effect of placebo was compared with a megadose of MP (30 mg/kg bolus followed by 5.4 mg/ kg/hour infusion over 23 hours). Another group received naloxone, an opiate antagonist, which had shown promise in previous animal experiments [39]. The NASCIS II Study included 487 patients who arrived to the hospital within 12 hours and were randomized to one of the treatment groups. Exclusion criteria included patients with isolated peripheral nerve injury (nerve root or cauda equina symptom), patients with other serious diseases, and pregnant women. A standard neurological examination was conducted on admission, after 6 weeks, 6 months, and 1 year. Motor function was evaluated in 14 muscle groups, and power was graded from 0 to 5. This means that the total score would be between 0 and 70 points. Sensory function was also evaluated through pinprick and tactile sensation in 29 dermatomes (C2 to S5). The response was graded between 1 3, which means that the total score would range between 29 and 87 points. The patients were divided before statistical analysis into those in whom treatment was initiated within 8 hours and those who received treatment after 8 hours. Patients were then subdivided into those with complete SCI (no motor or sensory function below level of injury) and incomplete SCI (some spared function). The results were published as change in total score from the starting point (when the patient first presented to the hospital). Regarding the sensory function, patients who received MP had better outcome at 6 months as compared with the control group. However, this effect disappeared at 1 year. Improvement
3 F.T. Sayer et al. / The Spine Journal 6 (2006) in the motor function was statistically significant at 6 months and even after 1 year in the MP group compared with the control group (17.2 and 12.0 points improvement, respectively, p5.030). Naloxone showed similar effect to placebo for all modalities at all time points. Results were published in 1992, and the conclusion was to recommend MP within 8 hours after spinal cord injury [27]. NASCIS III The third study, NASCIS III, was conducted in In this study, only patients with SCI who presented within 8 hours were included. As in the previous study, pregnant women and patients with serious illness were excluded. A total of 499 patients were included and randomized to 30 mg/kg bolus followed by 5.4 mg/kg/hour infusion over 23 hours (24MP), a group that received MP bolus and infusion for 47 hours infusion (48MP) or MP bolus followed by tirilazad infusion. Tirilazad has the same lipid peroxidation effect as MP but lacks the glucocorticoid effect, which was hypothesized to be the biological effect of MP that would be helpful in acute SCI. A standard neurological examination was conducted on admission, after 6 weeks, 6 months, and 1 year. In addition to the motor and sensory score, the patient s functional recovery was measured by using the Functional Independence Measure (FIM) developed by the American Spinal Injury Association. This scale included self-care, sphincter control, mobility, locomotion, communication and social cognition. As in previous studies, analysis was carried out as change in total score. Follow-up after 6 months revealed no significant difference between the groups with regard to any modality. At that point, patients were divided into those who received treatment within 3 hours and those in whom treatment was initiated after 3 hours but less than 8 hours after SCI. After this statistical maneuver, there was a statistically significant difference in motor score in patients who received MP bolus and infusion for 47 hours infusion (48MP) compared with 24MP, in the groups treated between 3 and 8 hours after injury. This statistically significant difference was observed at 6 weeks and 6 months, but was less apparent at 1 year (p5.053). No similar recovery was observed for the sensory function in any group. No statistically significant difference was observed for FIM between the groups at 1 year [29]. The tirilazad group was similar to the 24-hour MP; however, no solid conclusion was drawn because in both groups the treatment was initiated with a bolus dose of MP. A scientific basis for reconsidering the role of MP in SCI follows: Critical evaluation of the NASCIS II NASCIS II has received intensive criticism on several important methodological, scientific, and statistical issues: 1) It was always hypothesized that the effect of MP would depend on the rapidity of its administration after SCI. The initial study plan was to include patients up to 12 hours after injury. However, during the study period this was changed to 8 hours without any logical explanation. It is clear that the authors have tested the effect at different time points and found that the best effect was at the 8-hour time point. Changing the time points after analyzing the data compromises their scientific value [38,41]. 2) Only right-sided motor scores were reported in NASCIS II, but bilateral sensory scores were reported. Lack of evidence describing left-sided motor scores and total body motor scores in NASCIS II is confusing [28,42 44]. 3) The data were presented as obtained from the whole study population; however, the fact is that in the groups that presented within 8 hours, only 62 patients of the placebo group and 65 of the MP group were analyzed. This means that statistical analysis was done on only 30% of the study population (487 patients) and the other 70% were excluded. 4) Results comparing complete and incomplete lesions were published in 1993 [28]. There was no statistically significant difference between the treatment and control groups in patients with complete SCI. The beneficial effect of MP was only observed in patients with incomplete SCI who presented and were treated within 8 hours. However, only 17 patients received MP and 22 had placebo in that group of patients with incomplete SCI. 5) There have been strange results indicating that all of these conclusions were based on statistical artifacts. For example, patients with incomplete SCI who received placebo within 8 hours had worse outcome not only as compared with patients with incomplete SCI who presented and received MP within 8 hours but also when compared with patients with incomplete SCI who presented after 8 hours and received placebo. Furthermore, the placebo group of patients with incomplete SCI who presented after 8 hours had almost identical outcome to patients treated with MP within 8 hours after injury. So MP had the same effect as placebo! The previously described difference between MP and placebo groups could be a result of problems with the control group [35,41]. 6) The study did not offer a standardized medical and surgical treatment regimen for patients in NASCIS II study. The medical management of study patients including monitoring, blood pressure augmentation, respiratory care, deep venous thrombosis prophylaxis, nutritional support, and initiation of rehabilitation activities was neither consistent within centers nor consistent from center to center. The timing and type of surgical intervention for individual patients was not documented. There was no consideration given to the independent effect that either aggressive medical management or surgery had, or may have had, on outcome [17,35,38,41,45].
4 338 F.T. Sayer et al. / The Spine Journal 6 (2006) ) Lack of a minimum motor impairment for inclusion (hence, patients with normal motor function were admitted to the study) and no vertebral level of injury cutoff [35,38,41]. 8) The failure to measure patient s functional recovery using the FIM to determine whether the modest improvement reported in neurological examination (change in motor scores) in the MP-treated patients had meaningful clinical significance to the injured patients [34,35,38,46,47]. Critical evaluation of The NASCIS III NASCIS III has been prone for criticism on three major issues: determination of optimum timing of therapy, method of motor assessment of SCI patients, and insignificant differences in motor recovery scores and functional outcome measures among study patients [17,35,38,41,45]. 1) More patients with normal motor score were randomized into the 24-hour MP group [35]. 2) There was some difference in the score of motor function in certain muscle groups, but the FIM was similar in all groups. These final recommendations seem to be based on motor recovery score improvement alone. 3) For optimum timing of therapy, time-to-treatment data were not offered or explained. Like the 8-hour time for treatment cutoff result that came from the NASCIS II study, the within 3 hours of injury versus the 3 to 8 hours after injury timeframes reported in NASCIS III seem arbitrary [35,38,41]. Itis not clear when it was decided to have the 3-hour time point as a cutoff point [35,38]. 4) Motor scores were reported as change in motor scores for the right side of the body. Left-side motor scores and total body motor scores were not provided. The failure to provide this scientific data suggests that changes on the right side were the only findings that approach significance at 1 year (p 5.053) and argue against the meaningful nature of the data as interpreted and provided by the authors [35,38,41]. 5) Finally, the clinical relevance of the changes in motor scores between groups, in light of the nonsignificant differences in patient function as determined by FIM scores, is not evident. 6) Lack of standardized medical and surgical treatment. 7) Lack of a minimum motor impairment for inclusion (hence, patients with normal motor function were admitted to the study) and no vertebral level of injury cutoff [35,38,41]. Other clinical studies of MP treatment in SCI Others could not reproduce results obtained in the NASCIS II and III. Here we will review the most relevant clinical studies. Several other double-blind studies, comparing MP with placebo, were not published mostly because of the great publicity that MP received that made comparing it with placebo unethical. In 1993, Galandiuk et al. [48] studied 32 patients with cervical or upper thoracic SCI managed in an urban trauma center from January 1987 to February Fourteen patients who received NASCIS II doses of MP within 8 hours of injury were compared with 18 patients with similar injuries managed without corticosteroids. There was no difference in neurological outcome between the MP and control groups. However, the MP-treated patients had immune response alterations, a higher rate of pneumonia, and longer hospital stays as compared with the control group. The scientific value of this study was compromised by the mix of historical patients with contemporary patients, the lack of a prospective design, and the haphazard assignment and assessment of patients. Gerhart et al., in 1995 [49], reported a population-based, concurrent cohort comparison study of 363 SCI survivors treated in Colorado (218 SCI survivors injured between May 1, 1990 and December 31, 1991, and 145 persons spinal cord injured 2 years later, during 1993). There were no significant differences in outcome as assessed by the Frankel scale at the time of hospital discharge when 188 patients who received protocol MP were compared with those (n590) who did not receive any MP during treatment. This was a retrospective study, and the number of patients in each group was small enough to compromise the statistical power of this study. In 1995, George et al. [50] compared the outcome of 145 acute SCI patients: 80 treated with MP and 65 with no MP. There was no statistically significant difference in mortality or neurological outcome between patients treated with MP and those who were not. It is unclear from the study why most patients did not receive corticosteroid therapy, and this is the weakness of a nonrandomized study in which patient assignment to treatment may introduce bias. Gerndt et al., in 1997 [51] reported a retrospective review of 140 patients with SCI admitted within 8 hours of injury: 93 patients who received MP according to the NASCIS II protocol and 47 patients who received no corticosteroid. MP therapy was associated with a 2.6-fold increase in the incidence of pneumonia and an increase in ventilated and intensive care days. However, it was associated with a decrease in duration of rehabilitation and had no significant impact on other outcome parameters, including mortality. In 1997, Poynton et al. [52] reviewed 71 consecutive SCI patients managed at the National Spinal Trauma Unit in Dublin, Ireland. The objective was to determine the factors influencing neurological recovery. A total of 63 patients were available for follow-up at a mean of 29.6 months. The American Spinal Injury Association scoring system was used on admission and at follow-up to determine change in neurological status. They found no difference in neurological outcome between patients treated with MP and those who were not.
5 F.T. Sayer et al. / The Spine Journal 6 (2006) Table 1 Experimental studies where MP was shown to be neuroprotective Author Journal Species Experimental design Route of administration Evaluation parameters Fu and Saporta J Neurosurg Anesthesiol. Rat Aneurysm clip, saline Subcutaneous Biochemical interleukin levals 2005 Apr as control Lee et al. J Korean Med Sci Feb Rat Spinal clamps, saline control Intravenous Behavioral electrophysiological (evoked potentials) Jiang et al. Int J Immunopathol Pharmacol Sep Dec Rat Compression Intraperitoneal Behavioral histology (tissue loss and astrogliosis) Nakashima et al Neuroreprot Oct Rat Weight-drop, saline control Intravenous Immunohistochemical (GDNF gene expression) Cayli et al. Eur Spine J Dec Rat Weight-drop, vehicle Intraperitoneal Behavioral (ethanol) control Yan et al. Exp Neurol Oct Rat Weight-drop Intravenous Immunohistochemical (TNF-alpha-receptor expression) Fukaya et al J Neurosurg Jan Cat Vascular clip Intravenous Electrophysiological (evoked potentials) Nash et al J Neurosci Aug Rat Transection Intravenous Histology Benton et al. Brain Res Mar Rat Transection Intravenous Biochemical, Taurine levels Perez-Espejo et al. Surg Neurol Oct Rat Compression Intraperitoneal Electrophysiological, (evoked potentials) Chen et al. Exp Neurol Mar Rat Transection Not available Histology Farooque et al. J Neurosurg Mar Rat Compression Intravenous Biochemcial (microdialysis, aminoacids) Baffour et al. J Neurosurg Jul Rat Compression Intravenous Histology, behavioral Koc et al. Res Exp Med (Berl) Rat Compression N/A Biochemical (MDA levels) Behrmann et al. Exp Neurol Mar Rat Compression Intravenous Behavioral, Histology Farooque et al. Acta Neurol Scand Jan Rat Compression Intravenous Behavioral Body water content Constantini and J Neurosurg Jan Rat Compression Intravenous Histology (lesion volume) Young Ross et al. Surg Neurol Dec Rat Compression Intravenous Behavioral, Electrophysiologic, and Anatomic De Ley and Leybaert J Neurotrauma Spring Cat Compression Intravenous Electrophysiologic, SCBF and interstitial Ca 12 and K 1 activity Rosenberg-Schaffer Brain Res Mar In vitro In vitro In vitro Neuron survival and Lucas Akdemir et al. Res Exp Med (Berl) Rat Compression Intravenous Evoked potentials, Tissue Na 1,K 1 Holtz et al. Acta Neurol Scand Jul Rat Compression Intravenous Behavioral, Autoradiography (SCBF) Braughler et al. J Neurosurg Jul Cats Compression Intravenous Behavioral, Histology Iizuka et al. J Neurosurg Jul Rat Compression Intravenous Histology Anderson et al. Cent Nerv Syst Trauma Cat Compression N/A Histology Laschinger et al. Ann Thorac Surg Nov N/A Aorta clamp Intravenous SCBF, SEPs Braughler and Hall J Neurosurg Aug Cat Weight-drop Intravenous Histology, Biochemical Hall et al. J Neurosurg Jul Cat Weight-drop Intravenous Histology, Biochemical Braughler and Hall J Neurosurg Aug Cat Weight-drop Intravenous Biochemical (Lactate and pyruvate metabolism) Young and Flamm J Neurosurg Nov Cat Weight-drop Intravenous SCBF Naftchi Peptides May Jun Cat Weight-drop N/A (SEPs), carotid arterial BP, abdominal aorta BF Anderson et al. J Neurosurg Jan Cat Weight-drop Intravenous Microvascular perfusion, Biochemical Means et al. J. Neurosurg Aug Cats Compression Intravenous Behavioral, Histology BF5blood flow; BP5blood pressure; GDNF5glial derived neurotrophic factor; MDA5malondialdehyde; MP5methylprednisolone; N/A5not available; SCBF5spinal cord blood flow; SEPs5somatosensory evoked potentials; TNF5tumor necrosis factor. Pointillart et al., in 2000 [46], conducted a prospective clinical study in which 106 SCI patients were randomized into four groups: MP (according to the NASCIS II protocol), nimodipine, both agents, and neither medication. Neurological assessment (American Spinal Injury Association score) before treatment and at 1-year follow-up showed no statistically significant difference between groups. Short et al. [34] conducted an evidence-based review of the medical literature on the use of MP for SCI (animal and human experimental studies, including randomized human
6 340 F.T. Sayer et al. / The Spine Journal 6 (2006) Table 2 Experimental studies where MP was not shown to be neuroprotective Author Journal Species Experimental design Route of administration Evaluation parameters Carlson et al. J Bone Joint Surg Am Jan Dog Compression Intravenous SCBF, SEPs Takami et al. J Neurotrauma May Rat Weight-drop Intravenous Behavioral, Histology Rabchevsky et al. J Neurosci Res Apr Rat Weight-drop Intravenous Behavioral, Histology Merola et al. J Orthop Trauma Mar Rat Weight-drop Intravenous Histology Haghighi et al. Spinal Cord Jan Rat Compression N/A Behavioral Koyanagi and Tator Neurol Res 1997 Jun;19(3): Rat Compression Intravenous SCBF, SEPs, Histology Review. Hal et al. J Neurosurgery Jun Cat Compression Intravenous Enzyme immunoassay Coates et al. Vet Surg Mar Apr Dog Weight-drop Intravenous Behavioral, Histology Ross and Tator Neurosurgery Sep Rat Compression Intravenous SCBF, Electrophysiological Xu et al. J Neurotrauma Fall Rat Weight-drop Intravenous Histology Benzel et al. J Spinal Discord Dec Rat Compression N/A Behavioral Hall J Neurosurg Mar Cat Weight-drop N/A SCBF Faden et al. J Neurosurg Apr Cat Weight-drop Intramuscular Behavioral, Histology Green et al. Surg Neurol Feb Rhesus monkeys Weight-drop Intravenous Behavioral MP5methylprednisolone; N/A5not available; SCBF5spinal cord blood flow; SEP5somatosensory evoked potentials. clinical trials). The evidence obtained from three clinical trials and six cohort study publications indicated that the high-dose MP should be excluded from consideration as an intervention for acute SCI. Furthermore, the validity and the functional significance of results obtained from 12 larger animal publications were of concern for many. They concluded that the available evidence does not support the use of MP in the treatment of SCI. Complications associated with MP treatment Besides the narrow trauma-to-treatment time window of 8 hours [49,50,53 55], the use of MP is associated with increased risk for infections [22,27,50]. In the NASCIS II, although not statistically significant, patients who received MP had a 2.6-fold higher incidence of pneumonia, required longer periods of assisted ventilation and more ICU time [51]. The NASCIS III patients who received 48MP treatment had a twofold higher incidence of severe pneumonia, a fourfold higher incidence of severe sepsis, and a sixfold higher incidence of death due to respiratory complications than patients in the 24MP treatment group [28,38]. These differences, although not statistically significant, raise questions about the safety of the 48-hour treatment strategy. A randomized, prospective, double-blind study showed that the difference in all complications Table 3 Clinical trials where MP was not shown to improve neurological outcome following spinal core injury Author Method Participants Results Limitations Bracken et al. 1984, RCT 330 total No significant difference in 100 mg vs mg daily for 10 days 1985 (NASCIS I) neurological recovery Prendergast et al Historical controls 29 MP No differences motor and sensory Design, penetrating injuries, small sample 25 no MP scores George et al Retrospective 80 MP 65 no MP Poorer discharge mobility in the MP group Design, FIM data on 45 MP and 25 no MP only Gerhardt et al Retrospective 363 No difference between MP protocol Design and not (Frankel scale) Levy et al Retrospective 55 MP 181 no MP Did not improve functional outcome (Frankel scale) Design, penetrating injuries Pointillart et al RCT 27 MP1 nimodipine 27 MP 27 nimodipine 27 no medication No difference between groups (ASIA motor, sensory, pain scores) Pollard and Apple 2003 Retrospective 412 total No correlation between motor recovery and compliance with NASCIS protocol Wang et al Retrospective 8 MP 22 no MP No statistical association between MP and neurological recovery Small sample Design Design, pediatric, small size ASIA5American Spinal Injury Association; FIM5Functional Independence Measure; MP5methylprednisolone; NASCIS5National Acute Spinal Cord Injury Study; RCT5randomized clinical trial.
7 F.T. Sayer et al. / The Spine Journal 6 (2006) between the MP and placebo groups was not statistically significant (p5.139). However, there was a higher incidence of pulmonary (p5.009) and gastrointestinal complications (p5.036) in the MP group as compared with the control group [56]. Moreover, its potential effect on the long-term prospects of neuronal regeneration is not well established [57,58]. Wing et al. [59] examined the effect of MP administered according to the NASCIS II protocol on avascular necrosis of the femoral heads of 91 SCI patients; 59 of these patients received the corticosteroid, and 32 did not. The authors estimated the relative risk of avascular necrosis with high-dose 24-hour MP therapy to be less than 5%. Discussion The literature search was conducted using the National Library of Medicine s search service (PubMed). Key words used for the search were Methylprednisolone, Spinal cord injury, Spine trauma, Secondary injury, The National Acute Spinal Cord Injury Study, NASCIS. The search period was Only articles published in peer group reviewed journals were included. For the clinical part, only clinical trials were included and a total of 15 publications were found to satisfy the review criteria. Review articles, metaanalysis, and commentaries were excluded. For the basic science studies, only experimental work testing the effect of MP on the injured spinal cord histology, physiology, or functional outcome in treated animals after experimental SCI was included. A total of 47 publications were found to satisfy the review criteria. Although there is an abundance of evidence from experimental work supporting the use of MP (33 pro and 14 con MP) (Tables 1 and 2), the interpretation of these results is not easy where different animal species, experimental models, route of administration, dose of MP, and evaluation parameters were used. Furthermore, these results were not substantiated by clinical trials (3 pro and 8 con MP) (Tables 3 and 4). Despite the great variation in approach to elucidate the role of MP in SCI, no single publication has shown a clear superiority of MP over other agents or vehicle. An interesting observation was that, with a few exceptions, none of the researchers who have shown that MP has a neuroprotective effect revisited the issue. For example, if a study showed through behavioral or histopathological evaluation a positive effect of MP, then the logical continuation would be to investigate the issue at the molecular level. This would aim mainly to find a possible explanation for the observed positive effect, which could be used to exploit this therapeutic approach further. The clinical papers advocating the use of MP were all, except for three, published by the same group of authors. Although the results obtained from the NASCIS studies were statistically significant, there was no corresponding clinically obvious effect. This can be seen by the large number of review articles, meta-analyses, and commentaries written by experienced neurosurgeons and neurologists indicating their skepticism regarding the efficacy of MP in SCI. One of the major strengths of the NASCIS studies was the ability to recruit several hundred patients into the study. This has only been possible, until now, in the United States because of its large population size, incidence of SCI, and interest in this kind of research. Other clinical trials from other parts of the world included only a small number of patients, and this limited their comparability to the NASCIS studies. This might explain the large number of meta-analysis and review articles by those who do not believe in MP as a treatment in SCI. The problem for a physician responsible for the care of patients with SCI is that not using MP in the light of current evidence might lead to medico-legal problems. A possible way to solve this dilemma is to have multinational studies (eg, European Union level) or another study in the United States to be conducted by another group of researchers. The Food and Drug Administration and National Institutes of Health are possible candidates to play a leading role in this effort. Conclusion Based on the background of the enormous criticism that the NASCIS II and III have attained in the last few years, there have been many neurosurgical departments that have stopped using MP as a standard routine in acute SCI [36,60]. It is also important to note that MP is not recommended for use in acute SCI according to the Food and Drug Administration [35]. Table 4 Clinical trials where MP was shown to improve neurological outcome after spinal cord injury Author Method Participants Results Limitations Bracken et al. 1990, 1991, 1992 (NASCIS II) RCT 162 MP (154 naloxone) 171 placebo Increased recovery of neurological function (motor scores) MP!8 hr Only 62 MP/65 placebo in final analysis Bracken et al. 1997, 1998 RCT hr MP hr Improved neurological recovery Only motor scores, not FIM (NASCIS III) MP (166 tirilazade) 48-hr MP compared with 24-hr if 3 8 hr Aito et al Retrospective 65 total MP seemed to influence neurological outcome positively Design, small sample FIM5Functional Independence Measure; MP5methylprednisolone; NASCIS5National Acute Spinal Cord Injury Study.
8 342 F.T. Sayer et al. / The Spine Journal 6 (2006) Acute SCI is a catastrophic event that has severe consequences. The devastating nature of this type of injury should not be a motive to use treatments that lack a sound scientific and clinical basis. References [1] De Vivo MJ. Causes and cost of spinal cord injury in the United States. Spinal Cord 1997;35: [2] Vellacott PN, Webb-Johnson AE. Lancet 1919;i:173. [3] Frankel HL, Coll JR, Charlifue SW, et al. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord 1998;36: [4] Yeo JD, Walsh J, Rutkowski S, Soden R, Craven M, Middleton J. Mortality following spinal cord injury. Spinal Cord 1998;36: [5] McColl MA, Walker J, Stirling P, Wilkins R, Corey P. Expectations of life and health among spinal cord injured adults. Spinal Cord 1997; 35: [6] Kakulas BA. The clinical neuropathology of spinal cord injury: a guide to the future. Paraplegia 1987;25: [7] Bunge RP, Puckett WR, Becerra JL, Marcillo A, Quencer RM. Observations on the pathology of human spinal cord injury: a review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv Neurol 1993; 59: [8] Dusart I, Schwab ME. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci 1994;6: [9] Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol 1995;5: [10] Faden AI. Experimental neurobiology of central nervous system trauma. Crit Rev Neurobiol 1993;7: [11] Taoka Y, Okajima K. Role of leukocytes in spinal cord injury in rats. J Neurotrauma 2000;17: [12] Blight AR. Morphometric analysis of blood vessels in chronic experimental spinal cord injury: hypervascularity and recovery of function. J Neurol Sci 1991;106: [13] Amar AP, Levy ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 1999;44: [14] Sypert GW. Thoracolumbar fusion techniques. Clin Neurosurg 1990;36: [15] Geisler FH, Dorsey FC, Coleman WP. Past and current clinical studies with GM-1 ganglioside in acute spinal cord injury. Ann Emerg Med 1993;22: [16] Olsson Y, Sharma HS, Nyberg F, Westman J. The opioid receptor antagonist naloxone influences the pathophysiology of spinal cord injury. Prog Brain Res 1995;104: [17] Zeidman SM, Ling GS, Ducker TB, Ellenogen RG. Clinical applications of pharmacologic therapies for spinal cord injury: past and current clinical studies with GM-1 ganglioside in acute spinal cord injury. J Spinal Disord 1996;9: [18] Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal cord injury: a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991;324: [19] Geisler FH. GM-1 ganglioside and motor recovery following human spinal cord injury. J Emerg Med 1993;11: [20] Geisler FH. Clinical trials of pharmacotherapy for spinal cord injury. Ann NY Acad Sci 1998;845: [21] Clark WM, Hazel JS, Coull BM. Lazaroids: CNS pharmacology and current research. Drugs 1995;50: [22] Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazade mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 1997;277: [23] Petitjean ME, Pointillart V, Dixmerias F, et al. Traitement medicamenteux de la lesion medullaire traumatique au stade aigu. Ann Fr Anesth Reanim 1998;17: [24] Segal JL, Pathak MS, Hernandez JP, Himer PL, Brunnemann SR, Charter RS. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999;19: [25] Stein RB. Functional electrical stimulation after spinal cord injury. J Neurotrauma 1999;16: [26] Grijalva I, Guizar-Sahagun G, Castaneda-Hernandez G, et al. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. Pharmacotherapy 2003;23: [27] Bracken MB, Shepard MJ, Collins WF, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data: results of the Second National Acute Spinal Cord Injury Study. J Neurosurg 1992;76: [28] Bracken MB, Holford TR. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg 1993;79: [29] Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazade mesylate administration after acute spinal cord injury: 1-year follow-up data: results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 1998;89: [30] Faden AI, Jacobs TP, Smith MT, Zivin JA. Naloxone in experimental spinal cord ischemia: dose response studies. Eur J Pharm 1984;103: [31] Ross IB, Tator CH. Spinal cord blood flow and evoked potential responses after treatment with nimodipine or methylprednisolone in spinal cord injured rats. Neurosurgery 1993;33: [32] Ross IB, Tator CH, Theriault E. Effect of nimodipine or methylprednisolone on recovery from acute experimental spinal cord injury in rats. Surg Neurol 1993;40: [33] Koyanagi I, Tator CH. Effect of a single huge dose of methylprednisolone on blood flow, evoked potentials, and histology after acute spinal cord injury in the rat. Neurol Res 1997;19: [34] Short DJ, El Masry WS, Jones PW. High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective. Spinal Cord 2000;38: [35] Coleman WP, Benzel E, Cahill DW, et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 2000;13: [36] Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 2002;50(Suppl. 3): [37] Peter Vellman W, Hawkes AP, Lammertse DP. Administration of corticosteroids for acute spinal cord injury: the current practice of trauma medical directors and emergency medical system physician advisors. Spine 2003;28: [38] Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg (Spine) 2000;93:1 7. [39] Bracken MB, Shepard MJ, Hellenbrand KG, et al. Methylprednisolone and neurological function 1 year after spinal cord injury: results of the National Acute Spinal Cord Injury Study. J Neurosurgery 1985;63: [40] Bracken MB, Shepard MJ, Collins WF, et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322: [41] Nesathurai S. Steroids and spinal cord injury: revisiting the NASCIS 2 and NASCIS 3 trials. J Trauma 1998;45: [42] Young W, Bracken MB. The Second National Acute Spinal Cord Injury Study. J Neurotrauma 1992;9(Suppl. 1):S [43] Shepard MJ, Bracken MB. The effect of methylprednisolone, naloxone, and spinal cord trauma on four liver enzymes: observations from NASCIS 2. National Acute Spinal Cord Injury Study. Paraplegia 1994;32:
9 F.T. Sayer et al. / The Spine Journal 6 (2006) [44] Bracken MB. Cochrane Database Syst Rev 2000;(2):CD [45] Ducker TB, Zeidman SM. Spinal cord injury: role of steroid therapy. Spine 1994;19: [46] Pointillart V, Petitjean ME, Wiart L, et al. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 2000;38:71 6. [47] Acland RH, Anthony A, Inglis GS, Walton DI, Xiong X. Methylprednisolone use in acute spinal cord injury. N Z Med J 2001;114:99. [48] Galandiuk S, Raque G, Appel S, Polk HC. The two-edged sword of large-dose steroids for spinal cord trauma. Ann Surg 1993;218: [49] Gerhart KA, Johnson RL, Menconi J, Hoffman RE, Lammertse DP. Utilization and effectiveness of methylprednisolone in a populationbased sample of spinal cord injured persons. Paraplegia 1995;33: [50] George ER, Scholten DJ, Buechler CM, Jordan-Tibbs J, Mattice C, Albrecht RM. Failure of methylprednisolone to improve the outcome of spinal cord injuries. Am Surg 1995;61: [51] Gerndt SJ, Rodriguez JL, Pawlik JW, et al. Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma 1997;42: [52] Poynton AR, O Farrell DA, Shannon F, Murray P, McManus F, Walsh MG. An evaluation of the factors affecting neurological recovery following spinal cord injury. Injury 1997;28: [53] Prendergast MR, Saxe JM, Ledgerwood AM, Lucas CE, Lucas WF. Massive steroids do not reduce the zone of injury after penetrating spinal cord injury. J Trauma 1994;37: [54] Levy ML, Gans W, Wijesinghe HS, SooHoo WE, Adkins RH, Stillerman CB. Use of methylprednisolone as an adjunct in the management of patients with penetrating spinal cord injury: outcome analysis. Neurosurgery 1996;39: [55] Koc RK, Akdemir H, Karakücük EI, Ökem IS, Menkü A. Effect of methylprednisolone, tirilazad mesylate and vitamin E on lipid peroxidation after experimental spinal cord injury. Spinal Cord 1999;37: [56] Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M, Yamada H. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine 2001;26: [57] Hayashi M, Ueyama T, Tamaki T, Senba E. Expression of neurotrophin and IL-1 beta mrnas following spinal cord injury and the effects of methylprednisolone treatment. Kaibogaku Zasshi 1997;72: [58] Kell TA. The role of the immune system in central nervous system regeneration (theoretical considerations). Med Hypothesis 1988;26: [59] Wing PC, Nance P, Connell DG, Gagnon F. Risk of avascular necrosis following short-term megadose methylprednisolone treatment. Spinal Cord 1998;36: [60] Hugenholtz H. Methylprednisolone for acute spinal cord injury: not a standard of care. CMAJ 2003;168:
Pharmacological Management of Acute Spinal Cord Injury
SUPPLEMENT TO JAPI may 2012 VOL. 60 13 Pharmacological Management of Acute Spinal Cord Injury Alok Sharma * Introduction Medical care for acute spinal cord injury has advanced greatly in the last 50 years.
More informationTHE UTILITY OF STEROID IN SPINAL SURGERY; SYSTEMIC REVIEW
THE UTILITY OF STEROID IN SPINAL SURGERY; SYSTEMIC REVIEW Ram Ishwar Yadav 1*, Peng Jianqiao Matthew 1, Anand Mani Upadhyay 2 and Lincong Luo 3 Department of orthopedics, The First Affiliated Hospital
More informationSpinal Cord Injury. 1Demographics. 1.1 Incidence. 1.2 Causes. 2Neurological Level and Severity. 2.1 Level of Injury
Spinal Cord Injury 1Demographics 1.1 Incidence Varies from 29-50 per million population per year in USA to 9 per million population per year in Denmark. Mortality is decreasing improvement in EMS care
More informationReview of clinical trials of neuroprotection in acute spinal cord injury
Neurosurg Focus 6 (1):Article 8, 1999 Review of clinical trials of neuroprotection in acute spinal cord injury Charles H. Tator, M.D., Ph.D., and Michael G. Fehlings, M.D., Ph.D. Division of Neurosurgery,
More informationRole of methyleprednisolone succinate in the management of acute spinal cord injury
Original Article Role of methyleprednisolone succinate in the management of acute spinal cord injury NK Karn, BP Shrestha, GP Khanal, R Rijal, P Chaudhary, IP Mahato, N Das B.P. Koirala Institute of Health
More information総説 要 旨 Key words はじめに
86 167 173 2010 2010 4 1 2010 4 21 1954 Schneider 1 2 MRI T1 /T2 T1 /T2 Key words: 1 1 OPLL Koichi Hayashi, Masashi Yamazaki, Akihiko Okawa, Masao Koda, Masayuki Hashimoto and Kazuhisa Takahashi: Pathogenesis
More informationTraumatic spinal cord injury (TSCI) continues to be an
The Journal of TRAUMA Injury, Infection, and Critical Care Acute Traumatic Spinal Cord Injury, 1993 2000A Population- Based Assessment of Methylprednisolone Administration and Hospitalization Ernest Parrish
More informationJohn E. O Toole, Marjorie C. Wang, and Michael G. Kaiser
Hypothermia and Human Spinal Cord Injury: Updated Position Statement and Evidence Based Recommendations from the AANS/CNS Joint Section on Disorders of the Spine Peripheral Nerves John E. O Toole, Marjorie
More informationDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan
J Neurosurg (Spine 1) 98:56 62, 2003 Evaluation of time-dependent spread of tissue damage in experimental spinal cord injury by killed-end evoked potential: effect of high-dose methylprednisolone CHIKASHI
More informationEach year in the United States, SCI
Copyright 2007, Barrow Neurological Institute Multimodality Treatment of Spinal Cord Injury: Endogenous Stem Cells and Other Magic Bullets Eric M. Horn, MD, PhD Mark C. Preul, MD Volker K. H. Sonntag,
More informationSURGICAL SPINE INTERVENTION after traumatic spinal
1818 Outcomes of Early Surgical Management Versus Late or No Surgical Intervention After Acute Spinal Cord Injury William McKinley, MD, Michelle A. Meade, PhD, Steven Kirshblum, MD, Barbara Barnard, DO
More informationContemporary Management of Spinal Cord Injury
Contemporary Management of Spinal Cord Injury Ali Salim, MD Professor of Surgery Chief, Division of Trauma, Burns, Surgical Critical Care, and Emergency General Surgery Disclosures I have nothing to disclose
More informationThe Importance of Early Surgical Decompression for Acute Traumatic Spinal Cord Injury
Original Article Clinics in Orthopedic Surgery 2018;10:448-454 https://doi.org/10.4055/cios.2018.10.4.448 The Importance of Early Surgical Decompression for Acute Traumatic Spinal Cord Injury Dong-Yeong
More informationTraumatic Spinal Cord Injury. 39 th CANP Annual Educational Conference March 18 th, :00pm-6:15pm Carl Wherry, ACNP-bc Amanda Severson, ACNP-bc
Traumatic Spinal Cord Injury 39 th CANP Annual Educational Conference March 18 th, 2016 5:00pm-6:15pm Carl Wherry, ACNP-bc Amanda Severson, ACNP-bc Disclosures No conflicts of interest to disclose. Introduction
More informationMortality and Morbidity After High-Dose Methylprednisolone Treatment in Patients With Acute Cervical Spinal Cord Injury
1 of 9 2014/03/22 11:20 AM Mortality and Morbidity After High-Dose Methylprednisolone Treatment in Patients With Acute Cervical Spinal Cord Injury A Propensity-Matched Analysis Using a Nationwide Administrative
More informationMICHAEL B. BRACKEN, PH.D., AND THEODORE R. HOLFORD, PH.D.
See the Editorial and the Response in this issue, pp 257 258. J Neurosurg (Spine 3) 96:259 266, 2002 Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery
More informationFUNCTIONAL OUTCOMES OF TRAUMATIC PARAPLEGIA PATIENTS: DOES SURGERY IMPROVE THE QUALITY OF LIFE?
FUNCTIONAL OUTCOMES OF TRAUMATIC PARAPLEGIA PATIENTS: DOES SURGERY IMPROVE THE QUALITY OF LIFE? Original Article Orthopaedics R S Bajoria 1, Mahendra Panwar 2, Anand Rao 3, Sameer Gupta 4 1 - Associate
More informationSpinal injury. Structure of the spine
Spinal injury Structure of the spine Some understanding of the structure of the spine (spinal column) and the spinal cord is important as it helps your Neurosurgeon explain about the part of the spine
More informationDaniel W. Spaite, MD Vatsal Chikani, MPH Bentley J. Bobrow, MD Michael Sotelo, BS Bruce Barnhart, RN, CEP Kurt R. Denninghoff, MD Joshua B.
Daniel W. Spaite, MD Vatsal Chikani, MPH Bentley J. Bobrow, MD Michael Sotelo, BS Bruce Barnhart, RN, CEP Kurt R. Denninghoff, MD Joshua B. Gaither, MD Chad Viscusi, MD David P. Adelson, MD Duane Sherrill,
More informationTraumatic thoracic ASIA A examinations and potential for clinical trials
Thomas Jefferson University Jefferson Digital Commons Department of Neurosurgery Faculty Papers Department of Neurosurgery 11-2009 Traumatic thoracic ASIA A examinations and potential for clinical trials
More informationAntioxidative therapy in contusion spinal cord injury
(2009) 47, 458 463 & 2009 International Society All rights reserved 1362-4393/09 $32.00 www.nature.com/sc ORIGINAL ARTICLE Antioxidative therapy in contusion spinal cord injury AF Cristante, TEP Barros
More informationDELIRIUM IN ICU: Prevention and Management. Milind Baldi
DELIRIUM IN ICU: Prevention and Management Milind Baldi Contents Introduction Risk factors Assessment Prevention Management Introduction Delirium is a syndrome characterized by acute cerebral dysfunction
More informationGLYCEMIC CONTROL IN NEUROCRITICAL CARE PATIENTS
GLYCEMIC CONTROL IN NEUROCRITICAL CARE PATIENTS David Zygun MD MSc FRCPC Professor and Director Division of Critical Care Medicine University of Alberta Zone Clinical Department Head Critical Care Medicine,
More informationCervical Spine Surgery: Approach related outcome
Cervical Spine Surgery: Approach related outcome Hez Progect Israel 2016 Ran Harel, MD Spine Surgery Unit, Department of Neurosurgery, Sheba Medical Center, Ramat-Gan, Israel Sackler Medical School, Tel-Aviv
More informationA Phase I trial of naloxone treatment in acute spinal cord injury
J Neurosurg 3:390-397, 1985 A Phase I trial of naloxone treatment in acute spinal cord injury EUGENE S. FLAMM, M.D., WISE YOUNG, PH.D., M.D., WILLIAM F. COLLINS, M.D., JOSEPH PIEPMEIER, M.D., Gu~ L. CLIFTON,
More informationChinnock P, Roberts I This record should be cited as: Chinnock P, Roberts I. Gangliosides for acute spinal cord injury. (Protocol) The Cochrane Databa
T A B L E O F C O N T E N T S ABSTRACT...................................... BACKGROUND.................................... OBJECTIVES..................................... CRITERIA FOR CONSIDERING STUDIES
More informationGMl GANGLIOSIDES IN THE TREATMENT OF SPINAL CORD INJURY: REPORT OF PRELIMINARY DATA ANALYSIS
ACTA NEUROBIOL. EXP. 1990, 50: 515-521 Symposium "Recovery from brain damage: bel~avioral and neurochemical approaches" 4-7 July, 1989, Warsaw, Poland GMl GANGLIOSIDES IN THE TREATMENT OF SPINAL CORD INJURY:
More informationIntra-operative neurologic injuries: Avoidance and prompt response
Intra-operative neurologic injuries: Avoidance and prompt response James S. Harrop MD, FACS Professor Neurological and Orthopedic Surgery Director, Division of Spine and Peripheral Nerve Surgery Nsurg
More informationCurrent evidence in acute pain management. Jeremy Cashman
Current evidence in acute pain management Jeremy Cashman Optimal analgesia Best possible pain relief Lowest incidence of side effects Optimal analgesia Best possible pain relief Lowest incidence of side
More informationEpisode 66 Backboard and Collar Nightmares from EMU Conference. The Risks Associated with Backboard & Collar
However, backboards and collars are not without risk: Episode 66 Backboard and Collar Nightmares from EMU Conference With Dr. Kylie Bosman Prepared by Dr., edited by Dr. Kylie Bosman & Anton Helman, May
More informationNeuroprotection and Acute Spinal Cord Injury: A Reappraisal
NeuroRx : The Journal of the American Society for Experimental NeuroTherapeutics Neuroprotection and Acute Spinal Cord Injury: A Reappraisal Edward D. Hall and Joe E. Springer Spinal Cord and Brain Injury
More informationNeurologic improvement after thoracic, thoracolumbar, and lumbar spinal cord (conus medullaris) injuries
Thomas Jefferson University Jefferson Digital Commons Department of Orthopaedic Surgery Faculty Papers Department of Orthopaedic Surgery 1-2011 Neurologic improvement after thoracic, thoracolumbar, and
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress USE AND MISUSE OF GLUCOCORTICOIDS IN VETERINARY NEUROLOGY/NEUROSURGERY Richard A. LeCouteur, BVSc, PhD, DIP ACVIM
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationEffects of Methylprednisolone on the Neural Conduction of the Motor Evoked Potentials in Spinal Cord Injured Rats
J Korean Med Sci 25; 2: 132-8 ISSN 111-8934 Copyright The Korean Academy of Medical Sciences Effects of Methylprednisolone on the Neural Conduction of the Motor Evoked Potentials in Spinal Cord Injured
More informationInter-rater reliability of the 1992 international standards for neurological and functional classi cation of incomplete spinal cord injury
(2000) 38, 675 ± 679 ã 2000 International Medical Society of Paraplegia All rights reserved 1362 ± 4393/00 $15.00 www.nature.com/sc Inter-rater reliability of the 1992 international standards for neurological
More informationBIOMARKERS IN SEPSIS: DO THEY REALLY GUIDE US? Asist. Prof. M.D. Mehmet Akif KARAMERCAN Gazi University School of Medicine Depertment of Emergency
BIOMARKERS IN SEPSIS: DO THEY REALLY GUIDE US? Asist. Prof. M.D. Mehmet Akif KARAMERCAN Gazi University School of Medicine Depertment of Emergency Medicine 1 NO CONFLICT OF INTEREST 2 We do not fully understand
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: July 15, 2017 Related Policies: 1.01.05 Ultrasound Accelerated Fracture Healing Device 7.01.07 Electrical Bone Growth Stimulation of the Appendicular Skeleton
More informationTITLE: Optimal Oxygen Saturation Range for Adults Suffering from Traumatic Brain Injury: A Review of Patient Benefit, Harms, and Guidelines
TITLE: Optimal Oxygen Saturation Range for Adults Suffering from Traumatic Brain Injury: A Review of Patient Benefit, Harms, and Guidelines DATE: 11 April 2014 CONTEXT AND POLICY ISSUES Traumatic brain
More informationManagement Of Posttraumatic Spinal Instability (Neurosurgical Topics, No 3) READ ONLINE
Management Of Posttraumatic Spinal Instability (Neurosurgical Topics, No 3) READ ONLINE If you are searching for a ebook Management of Posttraumatic Spinal Instability (Neurosurgical Topics, No 3) in pdf
More informationSteroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye
Steroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye Steroids in ARDS: conclusion Give low-dose steroids if indicated for another problem
More informationJUST SAY NO? THE LATEST LOOK AT ACLS MEDICATIONS BRIDGETTE SVANCAREK, MD
JUST SAY NO? THE LATEST LOOK AT ACLS MEDICATIONS BRIDGETTE SVANCAREK, MD OBJECTIVES Review the progression of the American Heart Association s ACLS cardiac arrest medication guidelines Identify the latest
More informationAnimal Studies in Spinal Cord Injury: A Systematic Review of Methylprednisolone
ATLA 37, 43 62, 2009 43 Animal Studies in Spinal Cord Injury: A Systematic Review of Methylprednisolone Aysha Z. Akhtar, John J. Pippin and Chad B. Sandusky Physicians Committee for Responsible Medicine,
More information4/5/2018. Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY. I have no financial disclosures
Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY I have no financial disclosures 1 Objectives Why do we care about sepsis Understanding the core measures by Centers for Medicare
More informationSpinal Cord Injuries: The Basics. Kadre Sneddon POS Rounds October 1, 2003
Spinal Cord Injuries: The Basics Kadre Sneddon POS Rounds October 1, 2003 Anatomy Dorsal columntouch, vibration Corticospinal tract- UMN Anterior horn-lmn Spinothalamic tractpain, temperature (contralateral)
More informationMedical Policy Manual
Medical Policy Manual Policy Number: 0013 Effective Date: Reviewed Date: Next Review: August 2019 CLINICAL BACKGROUND INTRAOPERATIVE NEUROMONITORING BACKGROUND Intraoperative neurophysiologic monitoring
More information7 TI - Epidemiology of intracerebral hemorrhage.
1 TI - Multiple postoperative intracerebral haematomas remote from the site of craniotomy. AU - Rapana A, et al. SO - Br J Neurosurg. 1998 Aug;1():-8. Review. IDS - PMID: 1000 UI: 991958 TI - Cerebral
More informationLeo Happel, PhD Professor, Neurology, Neurosurgery, Physiology, and Neuroscience LSU Health Science Center
Leo Happel, PhD Professor, Neurology, Neurosurgery, Physiology, and Neuroscience LSU Health Science Center Leo Happel disclosed no financial relationships Vascular Lesions of the Spinal Cord The vast majority
More informationว ทยาการความก าวหน าในการร กษาผ ป วยบาดเจ บ กระด กส นหล งและไขส นหล ง. Piyawat Bintachitt, MD.
ว ทยาการความก าวหน าในการร กษาผ ป วยบาดเจ บ กระด กส นหล งและไขส นหล ง Piyawat Bintachitt, MD. Thank you Outline Pathophysiology Neurological classification Imaging Airway management Cardiovascular management
More informationLumbar Disc Prolapse: Management and Outcome Analysis of 96 Surgically treated Patients
Lumbar Disc Prolapse: Management and Outcome Analysis of 96 Surgically treated Patients A. Akbar ( Department of Neurosurgery, Chandka Medical College, Larkana. ) A. Mahar ( Department of Orthopedic Surgery,
More informationMedical Policy Manual. Topic: Peripheral Subcutaneous Field Stimulation Date of Origin: April Section: Surgery Last Reviewed Date: April 2014
Medical Policy Manual Topic: Peripheral Subcutaneous Field Stimulation Date of Origin: April 2013 Section: Surgery Last Reviewed Date: April 2014 Policy No: 188 Effective Date: July 1, 2014 IMPORTANT REMINDER
More informationAcute Care of Spinal Cord Injury. Meghan Smith, RN, PA-C
Acute Care of Spinal Cord Injury Meghan Smith, RN, PA-C Physician Assistant, Neuro Surgical, Trauma Services, Intermountain Medical Center, Intermountain Healthcare; Salt Lake City, Utah Objectives: Discuss
More informationClassification? Classification system should be: Comprehensive Usable Accurate Predictable Able to guide intervention
Moderator: Dr. P.S. Chandra Dr. Dr Deepak Gupta Classification? Classification system should be: Comprehensive Usable Accurate Predictable Able to guide intervention A precise, comprehensive, ideal
More informationCompleting the Circle: Novel Methods for using PRO Scores in Shared Decision- Making and Patient Self-Management.
Completing the Circle: Novel Methods for using PRO Scores in Shared Decision- Making and Patient Self-Management. Karon Cook, PhD, Northwestern University Chicago, IL Thursday, September 28, 2017 Relevant
More informationManagement of Bone and Spinal Cord in Spinal Surgery.
Management of Bone and Spinal Cord in Spinal Surgery. G. Saló, PhD, MD. Senior Consultant Spine Unit. Hospital del Mar. Barcelona. Ass. Prof. Universitat Autònoma de Barcelona. Introduction The management
More informationPARAPLEGIA. B FIG. 6 A, B and C, Same patient three years after spinal grafting shows a most remarkable improvement of spinal deformity and posture.
16 PARAPLEGIA A B FIG. 6 A, B and C, Same patient three years after spinal grafting shows a most remarkable improvement of spinal deformity and posture. a grotesque deformity of the spine and trunk with
More informationUpdate on early management of acute spinal cord injuries. Mr Jonathon L Richards Orthopaedic & Spinal surgeon
Update on early management of acute spinal cord injuries Mr Jonathon L Richards Orthopaedic & Spinal surgeon Overview: Aetiology/Cost Pathophysiology Early surgical intervention Emerging therapies Steroids
More informationPeripheral Subcutaneous Field Stimulation. Description
Subject: Peripheral Subcutaneous Field Stimulation Page: 1 of 6 Last Review Status/Date: June 2016 Peripheral Subcutaneous Field Stimulation Description Peripheral subcutaneous field stimulation (PSFS,
More informationMEDICAL POLICY SUBJECT: KETAMINE INFUSION THERAPY FOR THE TREATMENT OF CHRONIC PAIN SYNDROMES POLICY NUMBER: CATEGORY: Technology Assessment
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationNEUROLOGICAL IMPROVEMENT IN TRAUMATIC INJURIES OF CERVICAL SPINAL CORD. Rehabilitation Institute, Konstancin, Poland
Paraplegia 19 ('98,) 31-37 003 1-1758/8 I /01 22003 1$02.00 1981 International Medical Society of Paraplegia NEUROLOGICAL IMPROVEMENT IN TRAUMATIC INJURIES OF CERVICAL SPINAL CORD By }ERZY KIWERSKI and
More informationPartial vertebrectomy with vertebral shortening for. Key words: thoraco-lumbar fracturedislocation,
Romanian Neurosurgery (2014) XXI 2: 183-187 183 Partial vertebrectomy with vertebral shortening for thoraco-lumbar fracture-dislocation. Case report and technical note Bogdan Costachescu 1,2, Cezar E.
More informationDevelopment of a Clinical Tracheostomy Score to Identify Spinal Cord Injury Patients Requiring Prolonged Ventilator Support
Development of a Clinical Tracheostomy Score to Identify Spinal Cord Injury Patients Requiring Prolonged Ventilator Support Dane Scantling, Teerin Meckmongkol, Brendan McCracken Drexel University College
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29800 holds various files of this Leiden University dissertation. Author: Moojen, Wouter Anton Title: Introducing new implants and imaging techniques for
More informationAcute traumatic spinal cord injury (SCI) is a devastating
ORIGINAL RESEARCH B.G. Leypold A.E. Flanders A.S. Burns The Early Evolution of Spinal Cord Lesions on MR Imaging following Traumatic Spinal Cord Injury BACKGROUND AND PURPOSE: How early spinal cord injury
More informationEfficacy of postoperative epidural analgesia Block B M, Liu S S, Rowlingson A J, Cowan A R, Cowan J A, Wu C L
Efficacy of postoperative epidural analgesia Block B M, Liu S S, Rowlingson A J, Cowan A R, Cowan J A, Wu C L CRD summary This review evaluated the efficacy of post-operative epidural analgesia. The authors
More informationfactor for identifying unstable thoracolumbar fractures. There are clinical and radiological criteria
NMJ-Vol :2/ Issue:1/ Jan June 2013 Case Report Medical Sciences Progressive subluxation of thoracic wedge compression fracture with unidentified PLC injury Dr.Thalluri.Gopala krishnaiah* Dr.Voleti.Surya
More informationDefinition พ.ญ.ส ธ ดา เย นจ นทร. Epidemiology. Definition 5/25/2016. Seizures after stroke Can we predict? Poststroke seizure
Seizures after stroke Can we predict? พ.ญ.ส ธ ดา เย นจ นทร PMK Epilepsy Annual Meeting 2016 Definition Poststroke seizure : single or multiple convulsive episode(s) after stroke and thought to be related
More informationEAST MULTICENTER STUDY DATA DICTIONARY
EAST MULTICENTER STUDY DATA DICTIONARY Does the Addition of Daily Aspirin to Standard Deep Venous Thrombosis Prophylaxis Reduce the Rate of Venous Thromboembolic Events? Data Entry Points and appropriate
More informationNoah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018
Postnatal Steroids Use for Bronchopulmonary Dysplasia in 2018 + = Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 AAP Policy Statement - 2002 This statement is intended for
More informationA Structural Service Plan: Towards Better and Safer Spine Surgeries. Department of Orthopaedics & Traumatology Tuen Mun Hospital
A Structural Service Plan: Towards Better and Safer Spine Surgeries Department of Orthopaedics & Traumatology Tuen Mun Hospital Cheung KK Wong CY Chan Andrew Tse Alfred Chow YY Department of Orthopaedics
More informationLateral Mass and Pedicle Screws Fixation of Cervical Spine
Lateral Mass and Pedicle Screws Fixation of Cervical Spine Anderson Spine 1991 Paul A Anderson University of Wisconsin AAOS Biomedical Engineering Committee Co-chair ASTM F05-24 Purpose Anatomy Surgical
More informationPrediction of functional outcome after spinal cord injury: a task for the rehabilitation team and the patient
() 8, 8 ± ã International Medical Society of Paraplegia All rights reserved ± / $. www.nature.com/sc Prediction of functional outcome after spinal cord injury: a task for the rehabilitation team and the
More informationTHE NEUROLOGIC LEVEL after spinal cord injury (SCI)
389 Recovery of Upper-Extremity Strength in Complete and Incomplete Tetraplegia: A Multicenter Study John F. Ditunno, Jr., MD, Michelle E. Cohen, PhD, Walter W. Hauck, PhD, Amie B. Jackson, MD, Marca L.
More informationNeuroprotection. Key Points. What is neuroprotection? Secondary injury. Neuroprotection
Authors: SCIRE Community Team Reviewed by: Chris S. Bailey MD, FRCSC, MSc Last updated: Jan 22, 2018 describes a wide range of treatments that aim to protect the spinal cord from further damage in the
More informationHIGH LEVEL - Science
Learning Outcomes HIGH LEVEL - Science Describe the structure and function of the back and spine (8a) Outline the functional anatomy and physiology of the spinal cord and peripheral nerves (8a) Describe
More informationCentral Cord Syndrome: Does early surgical intervention improve neurological outcome
Central Cord Syndrome: Does early surgical intervention improve neurological outcome Ciara Stevenson, Jonathan Warnock, Suzanne Maguire, Niall Eames Department of Trauma and Orthopaedic Surgery, Royal
More informationDegenerative Disease of the Spine
Degenerative Disease of the Spine Introduction: I. Anatomy Talk Overview II. Overview of Disease Processes: A. Spondylosis B. Intervertebral Disc Disease III. Diagnosis IV. Therapy Introduction: Myelopathy
More informationPerformance Measure Name: TOB-3 Tobacco Use Treatment Provided or Offered at Discharge TOB-3a Tobacco Use Treatment at Discharge
Measure Information Form Collected For: The Joint Commission Only CMS Informational Only Measure Set: Tobacco Treatment (TOB) Set Measure ID #: Last Updated: New Measure Version 4.0 Performance Measure
More informationMRI of chronic spinal cord injury
The British Journal of Radiology, 76 (2003), 347 352 DOI: 10.1259/bjr/11881183 E 2003 The British Institute of Radiology Pictorial review MRI of chronic spinal cord injury 1 K POTTER, FRCR and 1 A SAIFUDDIN,
More information8.0 Parenteral Nutrition vs. Standard care January 31 st 2009
8.0 Parenteral Nutrition vs. Standard care January 31 st 2009 Recommendation: Based on 5 level 2 studies, in critically ill patients with an intact gastrointestinal tract, we recommend that parenteral
More informationArtificial Disc Replacement, Cervical
Artificial Disc Replacement, Cervical Policy Number: Original Effective Date: MM.06.001 02/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO 11/01/2011 Section: Surgery Place(s) of Service:
More informationTime Equals Neurons - Spinal Cord Injury Management in the first 4 Hours
Time Equals Neurons - Spinal Cord Injury Management in the first 4 Hours William D. Whetstone M.D. Clinical Professor UCSF Department of Emergency Medicine SFGH ED Center for Neuro-Critical Emergencies
More informationThought Field Therapy and Pain Robert Pasahow, PhD Diplomate, American Board of Medical Psychologists Director, Affiliates in Psychotherapy
Volume 11, Issue 2 Thought Field Therapy and Pain Robert Pasahow, PhD Diplomate, American Board of Medical Psychologists Director, Affiliates in Psychotherapy Chronic pain is such a prevalent problem that
More informationComplex Regional Pain Syndrome: Manifestations and the Role of Neurostimulation in Its Management
S20 Journal of Pain and Symptom Management Vol. 31 No. 4S April 2006 Special Article Complex Regional Pain Syndrome: Manifestations and the Role of Neurostimulation in Its Management Michael Stanton-Hicks
More informationSpinal Cord Injury Transection Injury, Spinal Shock, and Hermiated Disc. Copyright 2014, 2011, 2006 by Saunders, an imprint of Elsevier, Inc.
Spinal Cord Injury Transection Injury, Spinal Shock, and Hermiated Disc 1 Spinal Cord Injury Results from fracture and/or dislocation of vertebrae // Compresses, stretches, or tears spinal cord Cervical
More informationSpinal Cord Injury. North American Spine Society Public Education Series
Spinal Cord Injury North American Spine Society Public Education Series What Is a Spinal Cord Injury? A spinal cord injury is a condition that results from damage or trauma to the nerve tissue of the spine.
More informationTherapeutic Strategy for Traumatic Instability of Subaxial Cervical Spine
Chinese Medicine, 2009, 1, 23-29 Published Online September 2009 in SciRes (www.scirp.org/journal/cm) Therapeutic Strategy for Traumatic Instability of Subaxial Cervical Spine - ABSTRACT A simple, safe
More informationMULTIPLE CHOICE. Choose the one alternative that best completes the statement or answers the question.
EPC Ch 24 Quiz w-key Name MULTIPLE CHOICE. Choose the one alternative that best completes the statement or answers the question. 1) Which of the following best explains the presentation and prognosis of
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationSEP Monitoring. Outline. Outline 1/22/2015. Development of SEPs Stimulation and recording techniques Predictive value of SEP Uses of SEP monitoring
SEP Monitoring Andres A Gonzalez, MD Director, Surgical Neurophysiology Keck Medical Center of USC University of Southern California Outline Development of SEPs Stimulation and recording techniques Predictive
More informationControversies in Management of Spinal Trauma. Associate Professor John Moloney The Alfred Monash University
Controversies in Management of Spinal Trauma Associate Professor John Moloney The Alfred Monash University http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2989268/table/tab1/ Management continuum from the
More informationIs Cervical spine protection always necessary following penetrating neck injury
Is Cervical spine protection always necessary following penetrating neck injury Report By: Search checked by Institution: Date Submitted: Date Completed: Last Modified: Status: Carel Kruger - Senior Clinical
More informationSEP Monitoring. Andres A Gonzalez, MD Director, Surgical Neurophysiology Keck Medical Center of USC University of Southern California
SEP Monitoring Andres A Gonzalez, MD Director, Surgical Neurophysiology Keck Medical Center of USC University of Southern California Outline Development of SEPs Stimulation and recording techniques Predictive
More informationMisdiagnosis in cervical spondylosis myelopathy.
Journal of the International Society of Head and Neck Trauma (ISHANT) Case report Misdiagnosis in cervical spondylosis myelopathy. Dr. Reinel A. Junco Martin. Neurosurgeon. Assistant professor Miguel Enriquez
More informationEpinephrine Cardiovascular Emergencies Symposium 2018
Epinephrine Cardiovascular Emergencies Symposium 218 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN High Quality
More informationNuances of Spinal Radiculopathy. James Mallows
Nuances of Spinal Radiculopathy James Mallows Spinal dermatomes A dermatome is an area of skin that is mainly supplied by a single spinal nerve History of dermatomes Pioneering work by Sherrington (late
More informationDr. Park s SDR Publication
Dr. Park s SDR Publication Journal Papers 1. Phillips LH, Park TS: Electrophysiological mapping of the segmental anatomy of the muscles of the lower extremity. Muscle and Nerve 1991; 14:1213-121 2. Harris
More informationBilateral Foot Drop Without Cauda Equinae Syndrome Due To L4-L5 Disc Prolapse: A Case Report
ISPUB.COM The Internet Journal of Neurosurgery Volume 5 Number 1 Bilateral Foot Drop Without Cauda Equinae Syndrome Due To L4-L5 Disc Prolapse: A Case Report R Ramnaryan, C Palinikumar Citation R Ramnaryan,
More informationThe Management and Treatment of Ruptured Abdominal Aortic Aneurysm (RAAA)
The Management and Treatment of Ruptured Abdominal Aortic Aneurysm (RAAA) Disclosure Speaker name: Ren Wei, Li Zhui, Li Fenghe, Zhao Yu Department of Vascular Surgery, The First Affiliated Hospital of
More information